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Oxidized low-density lipoproteins (LDLs) play an important role during the development of atherosclerosis characterized by
intimal inﬂammation and macrophage accumulation. A key component of LDL is lysophosphatidylcholine (lysoPC). LysoPC
is a strong proinﬂammatory mediator, and its mechanism is uncertain, but it has been suggested to be mediated via the platelet
activatingfactor(PAF)receptor. Here,wereport thatPAFtriggersapertussistoxin-(PTX-)sensitiveintracellularsignalingpathway
leading to sequential activation of sPLA2,P L D ,c P L A 2, and AA release in human-derived monocytes. In contrast, lysoPC initiates
two signalingpathways, onesequentially activating PLD and cPLA2, and a second parallel PTX-sensitive pathwayactivating cPLA2
with concomitant activation of sPLA2, all leading to AA release. In conclusion, lysoPC and PAF stimulate AA release by divergent
pathways suggesting involvement of independent receptors. Elucidation of monocyte lysoPC-speciﬁc signaling mechanisms will
aid in the development of novel strategies for atherosclerosis prevention, diagnosis, and therapy.
1.Introduction
Lysophosphatidylcholine (lysoPC) is found at elevated levels
inatherosclerotic lesions [1]andhasbeenpostulatedtobean
important causal agent in inﬂammation and atherosclerosis.
It is a prominent phospholipid component of oxidized low-
densitylipoproteins(oxLDL),andwehaveearlier shown that
secretory phospholipase A2-( s P L A 2-) modiﬁed LDL [2]a n d
lysoPC alone [3] can induce proinﬂammatory activation of
human-derived monocytes by increased release of arachi-
donic acid (AA). LysoPC may be responsible for various
cellular processes such as regulation of monocyte adhesion
moleculeexpression[4],chemoattractant properties[5],and
monocyte proinﬂammatory cytokine secretion [6]. Some of
the intracellular signaling events initiated by lysoPC are the
activation of phospholipase D (PLD) [7, 8]a n ds t i m u l a -
tion of p38 and p42/44 mitogen-activated protein kinases
(MAPKs) through Gi/Go proteins [9]. Nevertheless, the sig-
naling mechanisms regulating speciﬁc cellular processes of
lysoPC are not completely understood.
It has been argued that lysoPC triggers cellular signaling
through G-protein-coupled receptors. To our knowledge,
three diﬀerent receptors have been suggested as lysoPC re-
sponsive receptors. First, evidence was presented showing
thatlysoPCinitiatesintracellularsignalingthroughtheplate-
let-activating factor (PAF) receptor [6, 8, 10], and it was hy-
pothesized that both lysoPC and PAF-induced common sig-
naling pathways through the PAF receptor. Later, two new
G-protein-coupled receptors speciﬁc to lysoPC, G2A and
GPR4, were described [11, 12]. However, the data show-
ing direct binding of lysoPC to these receptors have been re-
tracted due to their irreproducibility [13]. In spite of this,
there is still evidence of a functional relationship between
lysoPC and the G2A receptor [14–17]. In addition, lysoPC
has been reported to activate Gαs-proteins and induce apop-
tosisthrough theG2Areceptorin primary lymphocytes[17],2 Journal of Lipids
which indicates that the G2A receptor is a Gαs-receptor.
Hence,thereisstilluncertaintyifandhowlysoPCinducesin-
tracellular signaling.
PAF plays important roles in inﬂammation-mediating
cell-cell interactions in models of acute and chronic inﬂam-
mation in virtually all organs and induces cellular responses
through the G-protein-coupled PAF receptor [18]. Com-
pared to lysoPC, the intracellular signaling of PAF has been
extensively studied, and PAF is known to activate both PLD
and p38 MAPK through its receptor [19–22]. Additionally,
a protein kinase C-dependent PAF-induced pathway that
releases AA has been suggested [23]. PAF-induced cPLA2
activity is inhibited by pertussis toxin (PTX), suggesting Gαi-
protein involvement [24].
Enzymes that can mediate AA release are the PLA2
enzymes that hydrolyze fatty acids from the sn-2 position
in membrane phospholipids. This results in the generation
of biologically active lipids, such as free fatty acids and
lysophospholipids, all of which regulate inﬂammation. PLA2
enzymes comprise a large family that is diverse in structure,
biologicalfunction,mechanism, localization,andregulation,
and the isoenzymes are classiﬁed thereby [25]. cPLA2 is pref-
erentially arachidonyl selective and requires submicromolar
amounts of Ca2+ for activity [26, 27]. In a variety of cell
types, phosphorylation and activation of cPLA2 is brought
about by MAPK [28–30]. Extracellular PLA2, also referred
to as sPLA2, is secreted by cells in response to inﬂammatory
stimuli, and is thought to augment the inﬂammatory proc-
ess by catalyzing the production of lipid mediators. sPLA2
has been associated with many physiological and pathophy-
siological processes such as rheumatoid arthritis, sepsis, pso-
riasis, and atherosclerosis [31–33].
In order to examine if lysoPC intracellular signaling is
induced by an independent G-protein-coupled receptor, we
compared lysoPC- and PAF-induced intracellular signaling
components leading to AA release. Our results suggest that
PAF triggers a PTX-sensitive pathway leading to sequential
activation of sPLA2, PLD, and cPLA2 and AA release. In
contrast, lysoPC initiates two pathways, where one sequen-
tially activates PLD and cPLA2, and a second PTX-sensitive
pathway that activates cPLA2 with the simultaneous acti-
vation of sPLA2, all leading to AA release initiated from
independent receptors. In conclusion, our results suggest
that lysoPC indeed induces AA release via diﬀerent signaling
pathways compared to PAF. This supports the hypothesis of
divergent signalling pathways for the two lipids based on
their binding to unique receptors.
2.Materialsand Methods
2.1. Materials. RPMI 1640, gentamicin, lysoPC C:16, 2-
butanol, 3-(4,5-dimethylthiazol-2-yl)-2,5-difenyl tetrazoli-
um bromide (MTT), PTX, Triton-X100, EDTA, EGTA,
PMSF, and fatty acid-free bovine serum albumin (BSA)
were purchased from Sigma Chemical Co. (St. Louis, USA).
Fetal calf serum was obtained from Integro b.v. (Holland)
and WEB2170 from Boehringer Ingelheim (Germany).
[3H]AA and [14C]-L-3 phosphatidylcholine, 1 stearoyl-2-
arachidonyl were purchased from NEN (Boston, USA) and
methyl[14C]choline from Amersham LIFE SCIENCE (Buck-
inghamshire, England). Biologically active PAF C:16 and
methyl arachidonyl ﬂuorophosphonate (MAFP) were pur-
chased from Cayman Chemical (USA). NaOH, methanol,
HCl, NaCl, NH4OH, 1-butanol, aluminium sheets silica
gel 60 TLC plates, and chloroform were purchased from
Merck (Darmstadt, Germany). L-glutamine was obtained
fromGibcoBRL(LifeTechnologies,GrandIsland,NY,USA).
Leupeptin and pepstatin were obtained from Roche Diag-
nostics GmbH (Mannheim, Germany) and Bio-Rad reagent
was from Bio-Rad Laboratories (Hercules, USA). Group IIA
sPLA2 inhibitor, SB203347,wasgenerouslydonatedbyJames
Winkler, Smith Kline Beecham (Pharmaceuticals, Pa, USA).
2.2. Cell Culture. THP-1 cells were maintained in suspension
for passage and growth in RPMI 1640 containing 10%
(v/v) fetal calf serum, 3mg/mL glutamine, and 0.1mg/mL
gentamicin. The cells were grown with an initial density of
2 × 105 cells/mL and subcultured 2 times a week to ensure
continuous logarithmic growth in a humidiﬁed 5%v/v CO2
atmosphere. The THP-1 monocytes were when indicated
diﬀerentiated with 160nM PMA for 24h. Diﬀerentiation
from monocytes to macrophages was monitored by changes
in morphology and adherent capacity. The THP-1 cell line
was bought from ATCC and regularly checked for mycoplas-
ma contamination.
2.3. Measurement of Extracellular [3H] AA Release. THP-1
cells at 3 × 105 cells/well were labeled with [3H]AA (0,3μCi/
mL) and starved in 0.5%v/v FCS RPMI 1640 for 16h as
previously described [33]. Extracellular release of total [3H]
wasmeasuredbyscintillationcountingafterstimulationwith
lysoPC orPAF for indicated concentrationsand time periods
in RPMI 1640 containing 1mg/mL BSA. In experiments
using antagonists and inhibitors, WEB2170 was incubated
for 15min, alcohols and MAFP for 30min, SB203347 for
1h, and PTX for 2h prior to stimulation. Results are given
as released [3H]AA in the supernatant relative to [3H]AA
incorporated in the cells and are normalized to show fold
induction of treated relative to untreated cells. In experi-
ments with inhibitors, results are shown as percent inhibi-
tionoflysoPCofPAF-inducedcells. Resultsshown are repre-
sentative of three independent experiments.
2.4.RNAIsolation. TotalcellularRNAwasisolatedbyTRIzol
extraction according to the manufacturer’s instructions
(Gibco BRL, Life Technologies Inc., Grand Island, NY,
USA). Brieﬂy, cells were lysed and homogenized using Trizol
reagent.Chloroformwasaddedbeforecentrifugingforphase
separation. The aqueous phase with RNA was transferred
to a new tube, and RNA was precipitated by mixing the
aqueous phase with isopropyl alcohol. RNA was pelleted by
centrifuging and washed with ethanol before it was air-dried
and suspended in DEPC-treated water. RNA concentration
was determined by spectrophotometry at A260.
2.5. RT-PCR Detection of Diﬀerent PLD Isoforms. Total RNA
was reverse-transcribed and ampliﬁed by PCR as previously
described [3]. Conditions for RT-PCR were hPLD1a andJournal of Lipids 3
hPLD1b, 94◦C for 30sec, 60◦Cf o r1 m i n ,a n d7 2 ◦Cf o r
1min for 27 cycles and for hPLD2, 94◦Cf o r1 m i n ,5 6 ◦C
for 1.5min and 72◦C for 2min for 30 cycles. hPLD1a and
hPLD1b are transcript variants of the same gene and prim-
ers were designed to distinguish the two transcript vari-
ants, which results in products of 638bp (hPLD1a) and
533bp (hPLD1b) [34]. Primers used for ampliﬁcation were
synthesized as follows: hPLD1a and hPLD1b fwd 5 -TGG-
GCTCACCATGAGAA-3  (nucleotides 1475–1491) and rew
5 -GTCATGCCAGGGCATCCGGGG-3  (nucleotides2133–
2113)and hPLD2 fwd 5 -TCCATCCAGGCCATTCTGCAC-
3  (nucleotides 2802–2778) and rew 5 -CTATGTCCACAT-
TTCTAGGGGGAT-3  (nucleotides 2802–2778). All PCR
reactions were performed with water as the negative control
both for the RT reaction and PCR reaction (not shown).
2.6. PLD Choline Assay. THP-1 cells were starved in RPMI
1640 supplemented with 1mg/mL BSA and [14C]choline
(0.6μCi/mL) for 40h with a cell density of 6.75 × 105 cells/
well.ThecellswerestimulatedwithlysoPC(40μM,2min)or
PAF (40 μM,2min) inRPMI1640with1mg/mLBSA.Prein-
cubationswith inhibitors wereconductedundersame condi-
tions as forAA-release. To extract aqueousphase metabolites
the medium was centrifuged to remove cells before ice-cold
chloroform/methanol (1:2,v/v) was added.To the medium-
chloroform/methanol solution, ice-cold chloroform and wa-
ter was added to a ﬁnal ratio of methanol/chloroform/water
(2:2:1, v/v/v). The solution was mixed well and centrifuged
(500g, 5min) to separate the organic phase from the water
phase. The upper aqueous phase was evaporated to dryness
in a vacuum dryer overnight and resolved in water/ethanol
(1:1, v/v). Free choline was separated from phospho-
choline by TLC on aluminum silica gel 60 sheet developed
with 0.9%w/v NaCl/methanol/NH4OH (50:50:5,v/v/v).
Released choline in the medium was measured by Phospho-
Imager. 1M NaOH were added to the cells and the radioac-
tivity was measured by liquid scintillation counting to deter-
mine total radioactivity in cells. Results are expressed as re-
leased choline in the medium relative to total radioactivity
and are normalized to show fold induction of treated relative
to untreated cells. In experiments with inhibitors, results are
shown as percent inhibition of lysoPC or PAF-induced cells.
Percent inhibition is calculated with data retracted from the
background noise. Results given are representative of three
independent experiments.
2.7. cPLA2 In Vitro Assay. cPLA2 activity was measured as
described previously [35]. In brief, THP-1 cells were seeded
(2 × 106 cells/well) and starved (0,5%v/v FCS, 18h) before
stimulation with lysoPC (40μM, 10min) or PAF (40μM,
5min). Preincubations with inhibitors were done under the
same conditions as for AA-release. The cells were lysed in
lysis buﬀer and protein concentrations were measured by
BioRad protein reagent. 100μg lysate was incubated with
[14C]-L-3 phosphatidylcholine, 1 steroyl-2-arachidonyl-mi-
celles (100μM) at 37◦ centigrade for 30min before lipid
extraction by the Bligh and Dyer method [36]. Free AA was
separated from other phospholipids by TLC on aluminum
silica gel 60 sheets developed with ethyl acetate/isooctane/
acetic acid/water (55/75/8/100, v/v/v/v). The amount of
produced AA was detected by Phosphor-Imager and the
cPLA2 activity was expressed as a percentage relative to total
amount of phospholipids. In experiments with inhibitors,
results are shown as percent inhibition of lysoPC or PAF-
induced cells. Percent inhibition is calculated with data
retracted from the background noise. Results shown are
representative of three independent experiments.
2.8. MTT Cytotoxicity Assay. LysoPC and diﬀerent chemical
inhibitors were tested for cytotoxicity by MTT assay as
previously described [37]. The MTT assay reﬂects the
mitochondrial dehydrogenase activity, and the absorbance at
5 8 0n mw a su s e da sa ni n d e xo fc e l lv i a b i l i t y .
2.9. Statistics. The data are shown as means ± SDofseparate
experiments each containing 3 parallels (arachidonate and
PLD assay) or2parallels (cPLA2assay). Forthearachidonate
and PLD assay, the data of three independent experiments
were compared with the Kruskal-Wallis test for random
samples, and those at P<0.05 were considered signiﬁcant.
Each set of experiments was repeated three times.
3.Results
3.1. LysoPC and PAF Stimulate [3H]AA Release in THP-1
Cells. We have earlier shown that lysoPC stimulates [3H]AA
and [14C]OA release in the human-derived monocytic cell
line, THP-1, mediated both by sPLA2 and cPLA2 [3]. In
order to achieve a more detailed understanding of the mech-
anism of the lysoPC-induced pathway and, additionally, to
distinguish it from pathways induced by other lysolipid
analogues,wetestedanaloguessuchaslysophosphatidicacid,
sphingosylphosphorylcholine (conc. ranging from 20 to
100μM and stimulation time varying from 10 to 120min,
results not shown), and PAF for their ability to trigger AA
release. Among the analogues tested, only PAF could induce
signiﬁcant AA release (Figure 1). PAF-stimulated [3H]AA
release in a dose- and time-dependent manner with a
maximalreleaseafterﬁveminutes(Figure 1(a))atanoptimal
concentration of 35μMP A F( Figure 1(b)). Comparatively,
lysoPC stimulated AA release with a maximum after ten
minutes atan optimalconcentrationof40μM[3].Hence,we
observed that PAF elicits AA release with slightly more rapid
kinetics compared to lysoPC.
It is diﬃcult to deﬁne PAF’s “physiological concentra-
tion”,buttheoptimalconcentrationsofPAFandlysoPCwere
selected based on the criteria that the cells were viable, as
measured by MTT assay [38–40]. To enhance the sensitivity
of the AA assay, fatty acid-free BSA was added to the
media. Hence, the ﬁnal concentrations of free lipid in the
stimulation media were less than the actual concentration
used [41]. By stimulating THP-1 monocytes with 40μM
lysoPC for 10min or 35μM PAF for 5min, we did get a fold
increase in AA release between 3 to 12.
In order to determine which PLA2 enzymes contribute
to AA release, diﬀerent PLA2 inhibitors were applied. The
sPLA2 inhibitor, SB203347, reduced PAF-stimulated AA
release by 80%v/v (Figure 1(c)), while the cPLA2/iPLA24 Journal of Lipids
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Figure1:PAFand[3H]AAreleaseinhumanmonocytes.Prelabeled THP-1cells werestimulatedwithPAF,and[3H]AAreleasewasmeasured
by liquid scintillation counting. (a) The time course of PAF- (35μM) mediated [3H]AA. (b) PAF stimulation for 5min mediates [3H]AA
release in a dose-dependent matter. (c) Shows inhibition of PAF-induced [3H]AA by the sPLA2 inhibitor SB203347 (10μM) and the cPLA2
inhibitor MAFP (10μM). The PAF concentration used is 35μM. Data are expressed as means ± SD of triplicate determinations within
separate experiments. Asterisks indicate that values are statistically diﬀerent from PAF-treated cells (∗).
inhibitor, MAFP, reduced AA release by 60%v/v
(Figure 1(c)). Consequently, our results suggest that PAF
stimulate cPLA2 or iPLA2 activity; hence, the cPLA2 activity
assay is used later in this study to further assess cPLA2
activation. Our results suggest that PAF-stimulated AA re-
lease is mediated by sPLA2 and cPLA2 or iPLA2 in THP-1
cells, similar to the lysoPC-triggered response.
3.2. LysoPC and PAF Stimulate PLD Activity by Independent
Mechanisms. Ithasbeenshown thatlysoPC[8]andP AF[19]
stimulate PLD activity in mouse peritoneal macrophages.
PLD is a widely expressed enzyme, of which there are three
mammalian isoforms, PLD1a, PLD1b, and PLD2 [42]; all
threeisoenzymesareexpressed inhumanmonocytes[43].To
our knowledge, the expression of PLD isoenzymes in THP-1
cells has not been analyzed. To assess which PLD enzymes
were expressed, the PLD mRNA expression pattern was ana-
lyzed by RT-PCR. We did indeed ﬁnd expression of PLD1a
and PLD2 in both undiﬀerentiated and diﬀerentiated THP-1
cells, while PLD1b was faintly expressed in undiﬀerentiated
cells and clearly upregulated in diﬀerentiated THP-1 cells
(Figure 2). Since we use undiﬀerentiated THP-1 cells in this
study, any PLD activity we measure would be due mainly to
PLD1a and/or PLD2.Journal of Lipids 5
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Figure 2: Expression of PLD isoforms in THP-1 cells. RT-PCR
with primers speciﬁc for diﬀerent PLD isoforms (PLD1a 638bp,
PLD1b 533bp, and PLD2 710bp) was performed on total RNA
isolatedfromundiﬀerentiated THP-1,THP-1 cells diﬀerentiated for
72h and 120h (lanes 2,3, and 4, resp.; lane 1 is the positive con-
trol). Band intensities were calculated using BioRad image analysis
softwareandfoldinductionofPLDmRNAs(normalizedtob-actin)
relative to undiﬀerentiated cells is shown in the lower panel.
In order to determine if PLD is involved in lysoPC- and
PAF-stimulated AA release in human-derived monocytes,
[3H]AA prelabeled THP-1 cells were preincubated with the
primary alcohols 1-butanol and ethanol and with the sec-
ondary alcohol 2-butanol. The primary alcohols, but not the
secondary alcohol 2-butanol, will attenuate signaling medi-
ated by PLD, as they compete with water to be the hydroxyl
donor in the hydrolysis of phospholipids by PLD. [3H]AA
release in response to lysoPC and PAF stimulation was par-
tially inhibited by the two primary alcohols, 1-butanol and
ethanol (Figure 3) although ethanol was less eﬀective in
inhibiting [3H]AA release by PAF than by lysoPC. As expect-
ed, the secondary alcohol, 2-butanol, did not inhibit [3H]AA
release (Figure 3) because of its inability to be a hydroxyl
donor. This suggests that the enzymatic product of PLD ac-
tivity, phosphatidic acid (PA), regulates lysoPC- and/or PAF-
stimulated AA release in THP-1 cells.
To further assess if PLD is activated by lysoPC or PAF,
PLD activity was analyzed by cellular release of [14C]choline.
Both lysoPC and PAF signiﬁcantly increased [14C]choline
release, which is an indication of PLD activity (Figure 4(a)).
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Figure 3: LysoPC- and PAF-mediated [3H]AA release is inhibited
by diﬀerent alcohols. Prelabeled THP-1 cells were preincubated
withdiﬀerentalcohols30minbefore challengewith lysoPC(40μM,
10min) or PAF (35μM, 5min). [3H]AA release in the medium
was measured by liquid scintillation counting. Data are expressed
as means ± SD of triplicate determinations within separate experi-
ments. Asterisks indicate that values are statistically diﬀerent from
PAF- or lysoPC-treated cells (∗).
Optimal release was at40μM after2 minutesforbothlysoPC
and PAF. This suggests that both lysoPC and PAF stimulate
PLD activity.
PAF receptor is a G-protein coupled receptor and lysoPC
is also believed to mediate intracellular signaling through
G-protein-coupled receptors. To determine if diﬀerent G-
protein coupled receptors were involved in PLD activation,
we applied diﬀerent inhibitors to the cells before stimulation
of PLD activity. The PAF antagonist WEB2170 (10μM)
inhibited [14C]choline release in response to lysoPC by 80%
(Figure 4(b)) and in response to PAF by 90% (Figure 4(c)).
The PAF receptor is regulated by Gαi-proteins [24]. The
Gαi-protein inhibitor PTX inhibited lysoPC-induced PLD
activation by about 30% (Figure 4(b)) and PAF-induced
PLD activation by 70% (Figure 4(c)), suggesting that a Gαi-
protein is more central in the PAF-initiated stimulation of
PLD compared to lysoPC.
SincesPLA2 involvementinthelysoPCandPAFsignaling
pathway is already suggested, we wanted to examine if sPLA2
mediates PLD activity. In order to determine if sPLA2 ac-
tivates PLD, the speciﬁc sPLA2 inhibitor SB203347 was ap-
plied in the PLD experiment. SB203347 inhibited PAF-in-
duced PLD activation by almost 100% (Figure 4(c)), while
lysoPC-induced PLD activation was inhibited only by 30%
(Figure 4(b)). This suggests that the PAF-induced pathway
requires sPLA2 for activation of PLD, while in the lysoPC
pathway, sPLA2 contributes poorly to PLD activation, which
is in accordance with a study in HEK293 cells [44]. Addi-
tionally, involvement of Gαi-proteins is more prominent in
PAF-stimulated PLD activation compared to lysoPC-stimu-
lated activation. Taken together, this suggests that divergent
intracellular signaling pathways are initiated by lysoPC and
PAF.6 Journal of Lipids
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Figure 4: LysoPC and PAF stimulate PLD activity. (a) [14C]choline prelabeled THP-1 cells were stimulated with lysoPC or PAF for two
minutes, and [14C]choline released in the medium was measured after TLC separation. (b) and (c) [14C]choline prelabeled THP-1 cells were
preincubated with WEB2170, SB203347, or PTX before (b) lysoPC or (c) PAF challenge. Data are expressed as means ± SD of triplicate
determinations within separate experiments. Asterisks indicate that values are statistically diﬀerent from PAF- or lysoPC-treated cells (∗).
3.3. cPLA2 Activity Is Distinctively Stimulated in Response to
LysoPC and PAF. We have earlier shown that lysoPC stimu-
lates cPLA2 activity in human-derived monocytes [3]a n d
thatcPLA2 is involvedin PAF-mediated AArelease by inhibi-
tion with MAFP (Figure 1(c)). We examined cPLA2 activa-
tion in an in vitro assay, and our results showed that cPLA2
activity was signiﬁcantly induced by both lysoPC and PAF
(Figure 5(a)). LysoPC-induced responses are inhibited by
PAF-receptor antagonists [6, 8, 10], and it has been argued
that lysoPC might act through the PAF receptor. To investi-
gate if lysoPC-stimulated cPLA2 activity is induced by PAF
receptor, we applied the antagonist WEB2170 to the cells
prior to analysis of cPLA2 activity. LysoPC- and PAF-stimu-
lated cPLA2 activity was inhibited by WEB2170 by 40%
(Figure 5(b)) and 95% (Figure 5(c)), respectively. This indi-
cates that lysoPC acts partly through PAF receptorand partly
thought another unidentiﬁed receptor.
Both lysoPC and PAF are reported to activate PLD in
mouse peritoneal macrophages [8, 45]. In Figure 4(a),w e
show that PLD is activated in human-derived monocytes
by lysoPC or PAF. To analyze if PLD was involved in the
pathway activating cPLA2, we applied 1-butanol to the cells
before analysis of cPLA2 activity. As shown by the cPLA2 in
vitro activity assay, LysoPC- or PAF-induced cPLA2 activity
was indeed inhibited by 1-butanol (0.25%v/v) by 70%
(Figure 5(a)) and 95%(Figure 5(b)),which strongly suggests
that PLD is involved in cPLA2 activation although at a
signiﬁcantly higher degree in response to PAF compared toJournal of Lipids 7
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Figure 5: cPLA2 activity is diﬀerentially regulated by lysoPC and PAF. (a) cPLA2 enzyme assays were done on cell lysates treated with
lysoPCor PAF.(b) and (c) cPLA2 activity was determined in lysates from THP-1 monocytes treated with diﬀerent chemical inhibitors before
stimulation with (b) lysoPC or (c) PAF. Data are expressed as means ± SD of duplicate determinations within separate experiments. Data
shown are one representative of three independent experiments.
lysoPC stimulation. Again this suggests distinct signaling for
PAF and lysoPC.
We previously reported that sPLA2 contributes to
lysoPC-mediated AA release [3] ,a n da b o v e ,w eh a v es h o w n
for the ﬁrst time that sPLA2 also can contribute to PAF-
mediated AA release (Figure 1(c)). To analyze if sPLA2 regu-
lates lysoPC- or PAF-induced cPLA2 activity, we applied the
sPLA2 inhibitor SB203347. SB203347 inhibited PAF-stimu-
lated cPLA2 activity by 95% (Figure 5(c)), while lysoPC-in-
duced stimulation was dramatically less sensitive to the in-
hibitor (15% reduction, Figure 5(b)). These results indicate
that PAF-mediated cPLA2 activation is regulated by sPLA2;
however, lysoPC-mediated cPLA2 activity is poorly regulated
by sPLA2.
LysoPC has been reported to mediate signaling pathways
through Gαs-proteins [17]. In this study, we have used PTX,
which is a Gαi-protein inhibitor, in order to examine if Gαi-
proteins are involved in any of the pathways. PTX inhibited
potently both lysoPC-(Figure 5(b))a n dP A F - ( Figure 5(c))
induced cPLA2 activation by 100% and 68%, respectively,8 Journal of Lipids
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Figure 6:LysoPC-mediated[3H]AAreleaseisinhibitedby thePAF-receptor antagonistWEB2170.Prelabeled THP-1 cells werepreincubated
with WEB2170,stimulated with (a)lysoPC(40μM,10min.) or(b) PAF (35μM,5min)and [3H]AA release inthe medium wasmeasured by
liquid scintillation counting. Data are expressed as means ± SD of triplicate determinations within separate experiments. Asterisks indicate
that values are statistically diﬀerent from PAF- or lysoPC-treated cells (∗).
suggesting that cPLA2 activity inducedby lysoPCisregulated
through Gαi-proteins and to a lesser extent in the PAF-ini-
tiated pathway.
3.4. LysoPC and PAF-Stimulated [3H]AA Release Is Partly
BlockedbythePAFReceptorAntagonistWEB2170. Ithasbeen
reported that lysoPC may stimulate cellsvia the PAFreceptor
[6, 8, 10]. We compared the ability of the PAF receptor
antagonist WEB2170 to inhibit AA release by lysoPC and
PAF. WEB2170 inhibited both lysoPC- and PAF-stimulated
[3H]AA release by 40% (Figures 6(a) and 6(b))a t1 0 μM
WEB2170, suggesting that lysoPC acts partly through PAF
receptor and partly through another unidentiﬁed receptor.
This is similar to what is observed in HL-60 cells [46],
regarding lysoPC and PAF’s ability to initiate independent
signaling mechanisms.
4.Discussion
Takentogether,ourresultssuggestthatlysoPCandPAFdiﬀer
in the way they stimulate PLD and cPLA2 activation. PAF
stimulates PLD and cPLA2 activity in a sequential manner
mediated by sPLA2. In contrast, lysoPC sPLA2-induced AA
release appears to be in a very low extent dependent of PLD.
Moreover, cPLA2 istoalargeextentregulatedbyGαi-proteins
in the lysoPC pathway but to a lesser degree in the PAF
pathway (as shown in Figure 7).
PLD is reported to be activated in response to lysoPC
and PAF [10–12, 47]; however, PLD has, to our knowledge,
not been shown to be involved in lysoPC- or PAF-induced
AA release. We have shown here that there is an important
relationship between PLD, cPLA2, and consequently AA re-
lease. In addition, there is a striking diﬀerence upstream
of PLD in the two pathways leading to AA release, where
sPLA2mediates PLDactivation in response toPAFbutpartly
in response to lysoPC. These results suggest two divergent
pathways for lysoPC and PAF that earlier have been argued
to share common signaling pathways.
Several possible mechanisms have been suggested in the
literature about how PLD may aﬀect AA release. Firstly, PLD
may activate MAPK cascade that may contribute to phos-
phorylation of cPLA2 and consequently activation of the en-
zyme [28, 48]. We are currently investigating if p38 may be
an intermediate step between PLD and lysoPC induced AA
release. Secondly, PLD generates PA, which may be a sub-
strate for PLA2 enzymes [49]. Third, sequential activation
of PLD and phosphatidate phosphohydrolase results in DAG
accumulation. This facilitates the interaction of cPLA2 with
its substrate [50]. Thus, our results indicate that PLD is not
only important in generation of the key mediator PA but
also in activation of other enzymes such as cPLA2.T a k e n
together, PLD seems to be important in orderto diﬀerentiate
betweenthe lysoPC-and PAF-inducedintracellular signaling
pathways.
Previously, both lysoPC and PAF have been shown to
release AA in human-derived monocytes [3, 45]. Interest-
ingly, our results suggest that the AA release is a result of
two independent pathways,one initiated by PAFand a diﬀer-
ent pathway initiated by lysoPC. This novelty underscores
lysoPC and PAF’s ability to initiate and contribute to inﬂam-
mation through the activation of PLA2 enzymes and the
consequent release of AA, which is a precursor for the proin-
ﬂammatory hormones, the eicosanoids. Moreover, the two
distinct pathways triggered by the two lipids suggest that AA
release can be regulated by divergent pathways, mediating
similar proinﬂammatory response.Journal of Lipids 9
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Figure 7: Proposed main molecular mechanisms of intracellular signaling mediated by (a) PAF receptor and (b) unidentiﬁed lysoPC-
sensitive receptor. The ﬁgure shows enzymes in bold/italic and inhibitors in small letters with the sign “–|”.
PAF-stimulated AA release has in cell systems other
than monocytes been shown to be inhibited by the Gαi-
protein inhibitor, PTX, indicating that Gαi-proteins are
involved in PLA2 activation [51]. It is known that lysoPC can
mediate cellular responses through several G-proteins ([17]
and references herein). In our study, the PAF-mediated AA
releasing pathway was clearly regulated by a Gαi-protein. In
contrast, Gαi- p r o t e i n sw e r ei m p o r t a n tf o rc P L A 2 activation
but not as much in regulating PLD activity in response to
lysoPC. Thus, indicating a third pathway for AA release by
lysoPC. Hence, our results suggest that the PAF pathway
and in part the lysoPC pathway is triggered by Gαi-protein
coupled receptors.
It is well known that PAF induces intracellular signaling
through the G-protein coupled PAF receptor and that it is
inhibited by diﬀerent PAF antagonists such as WEB2170
[52].Inaddition, it isreported thatlysoPC-induced respons-
es may be inhibited by PAF-receptor antagonists [6, 8, 10],
and previous authors suggest that this indicates cellular
lysoPC-induced responses via the PAF receptor. We show
herethatbothlysoPC-andPAF-stimulatedcellularresponses
were inhibited by the PAF receptor antagonist, WEB2170 al-
though the intracellular signaling pathways inhibited clearly
were diﬀerent. The literature opens for the existence of
structurally related receptors eﬀectuating lysoPC- or PAF-
stimulated responses, and further studies will be necessary
to identify a speciﬁc receptor for lysoPC. Hence, our results
strongly suggest that lysoPC and PAF stimulate independent
signaling pathways leading to AA release are partly triggered
by independent receptors, but we are uncertain as to the
identity of the exact receptor responsible for the major
lysoPC-induced intracellular signaling.
In this study we come closer to resolving some of the
molecular mechanisms regulating AA release in response to
lysoPC in human-derived monocytes by comparing it to
that of its analogue PAF. In conclusion, our results suggest
separate pathways leading to AA release stimulated by PAF
compared to lysoPC (Figure 7). PAF triggers a PTX sensitive
pathway by sequentially activating sPLA2, PLD, and cPLA2,
while lysoPC triggers one pathway by sequentially activating
PLD and cPLA2, a second PTX sensitive pathway activating
cPLA2 and third pathway activating sPLA2. More detailed
understanding of intracellular signaling mechanisms will
allowforgreaterspeciﬁcityinthedesignoffuturetherapeutic
strategies.
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